Catalog No.
Product Name
Application
Product Information
Citations
-
EP1 Antagonist
GSK345931A is an EP1 receptor antagonist that demonstrates significant central nervous system penetration in murine models. It exhibits potent analgesic effects in both acute and sub-chronic inflammatory pain models, making it a valuable tool for exploring pain mechanisms and potential therapeutic applications in pain management research. -
DP2 Antagonist
MK-1029 is a potent DP2 antagonist that selectively inhibits the D-type prostaglandin receptor. This compound exhibits significant activity in modulating inflammatory responses and bronchoconstriction, making it a valuable tool for investigating respiratory diseases such as asthma. Its ability to block DP2 signaling pathways aids in understanding the underlying mechanisms of chronic airway diseases and evaluating potential therapeutic strategies. -
Antifertility Compound
L-10503 is a non-hormonal antifertility compound that operates through a unique mechanism distinct from traditional prostaglandin-based strategies. This compound exhibits significant inhibitory effects on reproductive processes, making it valuable for studying fertility regulation and contraceptive research. Its application extends to investigations of non-hormonal contraceptive methods and understanding the mechanisms underlying fertility. -
Isomer
(R)-L 888607 is the isomer of L 888607, serving as a valuable experimental control. As a potent and selective agonist of the CRTH2 receptor, it demonstrates high affinity, with a Ki value of 4 nM. This compound has applications in studying various physiological events and metabolites, providing insights into immune response modulation and related pathways. Its oral bioavailability further facilitates in vivo research applications. -
Aipogenic Agent
AD 4743 is an adipogenic agent with the primary mechanism of inducing the accumulation of FPRP and lipid droplets in cells. It has demonstrated the ability to inhibit the proliferation of preadipose cells, making it a valuable tool for research in adipogenesis and metabolic studies. This compound can be used to investigate the mechanisms of adipocyte differentiation and related metabolic processes. -
Prostaglandin Receptor Agonist
Irodanoprost is a potent agonist of prostaglandin receptors, playing a significant role in mediating osteogenesis. Its primary mechanism involves stimulating bone formation and remodeling, making it valuable for research into osteogenesis-related diseases. This compound is useful for studying the effects of prostaglandin signaling in various bone-related conditions. -
Stereoisomer
16(R)-Iloprost is a stereoisomer of the potent vasodilator Iloprost, primarily targeting the prostacyclin receptor. This compound demonstrates significant biological activity by inhibiting platelet aggregation, with an IC50 value of 65 nM. It is utilized in research applications involving cardiovascular studies and the exploration of thrombotic disorders. -
Prostacyclin Analog
(Rac)-Beraprost is an orally active prostacyclin analog that exerts its effects by binding to prostacyclin membrane receptors, which inhibits the release of Ca2+ from intracellular stores. This mechanism promotes smooth muscle cell relaxation and vasodilation. With notable vasodilatory, antiplatelet, and cytoprotective properties, (Rac)-Beraprost is a valuable reagent for research focused on cardiovascular conditions, including thromboangiitis obliterans and atherosclerosis. -
Bronchodilator
11-Deoxy prostaglandin E1 is a synthetic analog of prostaglandin E1 that functions primarily as a bronchodilator. It effectively inhibits histamine-induced bronchoconstriction and induces relaxation in tracheal strips from isolated guinea pigs. This compound is valuable for research applications focusing on respiratory physiology and the modulation of airway reactivity. -
CRTh2 Receptor Antagonist
NVP-QAV680 is a selective antagonist of the CRTh2 receptor, exhibiting low nanomolar potency in inhibiting CRTh2-mediated activation of human eosinophils and Th2 lymphocytes. This compound demonstrates significant oral bioavailability and has shown efficacy in models of CRTh2-dependent mechanisms and allergic diseases in rats. Its properties make NVP-QAV680 a valuable tool for research in allergy and immunology. -
FP Receptor Antagonist
AL 8810 methyl ester is a competitive antagonist of the prostaglandin F(2α) receptor (FP receptor). It effectively inhibits the biological activity of the FP receptor agonist Fluprostenol, allowing for detailed studies of FP receptor-mediated pathways. This compound does not exhibit significant potency against other prostaglandin receptor subtypes, including TP, DP, EP(2), and EP(4), making it a valuable tool for specific FP receptor research applications. -
Prostaglandin Metabolism Inhibitor
L11204 is a potent inhibitor of prostaglandin metabolism. It effectively inhibits PMS-induced superovulation, resulting in a reduced number of recoverable ova in the oviducts of hamsters. Additionally, L11204 demonstrates the capability to inhibit chorionic gonadotrophin-induced ovarian hypertrophy and steroidogenesis in rats. This compound shows promise for studying reproductive system disorders and related biological processes. -
Isoprostaglandin
15-A2t-Isoprostane is an isoprostaglandin formed through the non-enzymatic oxidation of arachidonic acid. This compound serves as a significant biomarker for oxidative stress and lipid peroxidation in biological systems. Its biological activities include the modulation of inflammation and vascular function, making it valuable for research in cardiovascular diseases and oxidative stress-related pathologies. -
Aromatase Activator
5-trans-PGE2 is a potent aromatase activator that serves a crucial role in the paracrine signaling pathway between epithelial cells and adjacent stromal cells. By enhancing the activity of aromatase, it influences estrogen biosynthesis, which is fundamental in the context of breast cancer growth and development. This compound is particularly valuable for research applications focused on hormone regulation and cancer biology. -
8-iso Prostaglandin E2 Derivative
8-Iso Prostaglandin E2 isopropyl ester is a derivative of 8-iso Prostaglandin E2, designed to enhance lipophilicity compared to its free acid counterpart. This compound exhibits significant biological activity, primarily functioning as a modulator of various signaling pathways involved in inflammation and cellular responses. It is commonly utilized in research applications to investigate the roles of prostaglandins in physiological and pathological processes. -
EP4 Antagonist
(R)-Vorbipiprant is a selective antagonist of the prostaglandin E2 receptor 4 (EP4), exhibiting a binding affinity (Ki) of 16.6 nM for human EP4. It effectively inhibits PGE2-induced cAMP production, with an IC50 value of 22 nM. This compound demonstrates significant immunomodulatory and anti-angiogenic properties, making it a valuable tool for research in inflammation and arthritis, particularly in models of collagen-induced arthritis in mice. -
Prostaglandin Receptor Inhibitor
1,2,3-Trilinoelaidoyl glycerol acts as a prostaglandin receptor inhibitor, influencing the biosynthesis of prostaglandins and modulating platelet function. This compound also demonstrates significant effects on the fatty acid composition within rat organs, depending on the dosage administered. It serves as a valuable tool for examining dietary impacts on lipid metabolism and associated physiological parameters in preclinical research involving rodent models. -
Thromboxane Synthase Inhibitor
Furegrelate is a selective thromboxane synthase inhibitor that acts primarily by blocking the synthesis of thromboxane A2 (TxA2) in human platelets, exhibiting an IC50 of 15 nM. Its potent inhibitory action makes Furegrelate a valuable candidate for research applications focused on antiplatelet therapies. This compound is under investigation for its potential to mitigate thrombotic events associated with cardiovascular diseases. -
FP Antagonist
TGI-15 is a highly selective antagonist of the prostaglandin F receptor (FP). By inhibiting the binding of PGF2α to FP receptors, TGI-15 disrupts downstream signaling pathways, making it a valuable tool for investigating fibrotic and inflammatory conditions. This compound is essential for research focused on the modulation of inflammation and fibrosis. -
Anti-bronchospasm Agent
16,16-Dimethylprostaglandin F2β is a synthetic analog of prostaglandin F2β with a primary action as an anti-bronchospasm agent. This compound effectively prevents bronchospasm induced by various irritants, making it valuable in respiratory research. Its ability to modulate bronchial smooth muscle responsiveness supports its application in studies related to asthma and other obstructive airway diseases. -
EP1 Prostaglandin Receptor Antagonist
EP1 receptor antagonist-1 is an antagonist of the EP1 prostaglandin receptor, which plays a critical role in mediating inflammatory responses. This compound demonstrates significant biological activity by inhibiting EP1 receptor signaling, making it valuable for research focused on urinary system-related diseases. Its potential applications include investigating pathways involved in urinary tract conditions and assessing therapeutic strategies targeting prostaglandin receptors. -
PGF2α Analogue
(+)-Cloprostenol sodium is a selective agonist of the prostaglandin F2α (PGF2α) receptor. It exhibits key biological activities such as promoting smooth muscle contraction and modulating uterine activity, making it valuable in reproductive research. This compound is typically employed in studies related to veterinary medicine and endocrinology, particularly in the regulation of reproductive processes. -
PGF2α Analog
15-Keto Bimatoprost is a potent prostaglandin F2α (PGF2α) analog that primarily targets ocular tissues. This compound exhibits significant biological activity in reducing intraocular pressure, making it valuable for research into therapies for glaucoma and other ocular hypertension conditions. Its mechanism of action facilitates enhanced aqueous humor outflow, providing insight into the regulation of intraocular pressure in various in vitro and in vivo studies. -
NSAID
Alclofenac (lysinate) is a non-steroidal anti-inflammatory drug (NSAID) that functions primarily as a prostaglandin H2 synthase inhibitor. It exhibits significant anti-inflammatory and analgesic properties, making it valuable for the study of conditions such as rheumatoid arthritis, degenerative joint disease, and ankylosing spondylitis. This compound is an essential tool for researchers investigating inflammatory pathways and evaluating potential therapeutic interventions in related diseases. -
hDP Agonist
L-644698 is a highly selective agonist of the human recombinant prostaglandin D2 (PGD2) receptor (hDP), exhibiting Ki values of 0.9 nM for hDP and significantly higher values for other receptors (hEP2, hEP3, hEP4). This compound stimulates cyclic AMP production with an EC50 of 0.5 nM, making it a valuable tool for researching PGD2 receptor signaling pathways and their implications in various biological processes. Its specificity and potency render L-644698 an essential reagent for studies aimed at understanding the role of hDP in physiological and pathological states. -
Prostaglandin Receptor
15-keto-17-phenyl trinor Prostaglandin F2α is a potent analog targeting prostaglandin receptors. It demonstrates significant biological activity by slightly reducing intraocular pressure in normal cynomolgus monkeys and effectively acting as a miotic agent in felines, notably decreasing pupil diameter. This compound is useful for research applications related to ocular physiology and the pharmacological effects of prostaglandin analogs. -
EP4 Receptor Antagonist
ASP7657 free base is a potent orally active antagonist of the EP4 receptor, exhibiting binding affinities (Kis) of 2.21 nM for human EP4 and 6.02 nM for rat EP4 receptors. This compound demonstrates significant biological activity in modulating inflammatory responses and is particularly useful in research focused on conditions related to pain, inflammation, and various immune disorders. Its selective action on the EP4 receptor makes it an important tool for investigating therapeutic strategies in relevant disease models. -
EP1/EP3 Receptor Agonist
Nocloprost is an orally active agonist of the EP1 and EP3 receptors, functioning as a prostaglandin E2 (PGE2) analog. This compound demonstrates significant biological activity by inhibiting evoked [3H]ACh release, showcasing its potential in neuroprotective research. Nocloprost exhibits gastroprotective and ulcer-healing properties, effectively accelerating the healing of chronic gastric ulcers and promoting mucosal growth in experimental models. As such, it serves as a valuable reagent for studying gastrointestinal health and related therapeutics. -
EP4 receptor Agonist
EP4 receptor agonist 3 selectively targets the EP4 receptor, functioning as an effective agonist. This compound is utilized in research applications related to inflammatory bowel disease, particularly in colitis models in mice induced by dextran sulfate sodium (DSS). Its activation of the EP4 receptor pathway offers valuable insights into potential therapeutic strategies and mechanisms underlying gastrointestinal inflammation. -
Thromboxane A2 Receptor Antagonist
CGS-22652 is a potent antagonist of the thromboxane A2 receptor. It exhibits selective inhibitory properties against thromboxane A2 synthase, making it valuable in studies investigating the role of thromboxane A2 in cardiovascular conditions. CGS-22652 is particularly relevant for research on coronary artery thrombosis and related thrombotic disorders. -
EP1 Receptor Agonist
17-Phenyl trinor prostaglandin E2 ethyl amide is a potent agonist of the EP1 receptor. This compound has been shown to exacerbate renal dysfunction and contribute to the progression of glomerulosclerosis. It serves as a valuable tool for studying the roles of EP1 receptor activation in renal pathophysiology and related research applications. -
Prostacycline Analogue
6β-Prostaglandin I1 is a stable analog of prostaglandin I2 (PGI2) that exhibits resistance to hydrolysis in aqueous environments. This compound is known for its ability to significantly reduce gastric acid secretion, with an ID50 of approximately 3.0 μg/kg/min when administered via intravenous injection. Its unique properties make it valuable for research applications in gastrointestinal physiology and the study of prostaglandin signaling pathways. -
Thromboxane Synthetase Inhibitor
UK 34787 is a selective thromboxane synthetase inhibitor that exhibits minimal activity against cyclooxygenase and prostacyclin synthetase. This compound is utilized in research to study thromboxane's role in cardiovascular function and various pathophysiological conditions. Its specificity makes it a valuable tool in investigating the therapeutic potential of thromboxane modulation in disease models. -
Thromboxane Synthase Inhibitor
Wy 27569 is a thromboxane synthase inhibitor that modulates prostaglandin balance by decreasing pro-thrombotic thromboxane A2 (TXA2) and increasing anti-thrombotic prostacyclin (PGI2). This compound is known for its vascular selectivity and ability to effectively lower blood pressure. Wy 27569 is utilized in research on cardiovascular diseases, including hypertension and angina, making it valuable for understanding thrombotic processes and vascular health. -
Thromboxane A2 Synthetase Inhibitor
Nafagrel hydrochloride is a potent thromboxane A2 synthetase inhibitor. This compound effectively prevents thrombus formation, demonstrated in a rat model of acute arterial thrombosis. It is valuable for research applications related to cardiovascular disease, thrombosis, and related therapeutic interventions. -
TAX2 Antagonist
I-SAP is a radioiodinated antagonist of the thromboxane A2 (TXA2)/prostaglandin H2 (PGH2) receptor. This compound effectively inhibits receptor binding, which can be altered by histidine-modifying agents such as diethyl-pyrocarbonate (DEPC). I-SAP is utilized in research related to cardiovascular biology, particularly in studies examining TXA2 signaling pathways and their physiological effects. -
Prostaglandin Receptor Antagonist
AH22921 is a selective antagonist of the EP4 prostaglandin receptor, inhibiting the activation of adenylate cyclase by prostaglandins in CHO cells. This compound is characterized by its ability to shift the PGE2 concentration-response curve to the right, demonstrating its non-competitive antagonistic effect specifically on EP4 receptors. Notably, AH22921 does not influence the PGE2 concentration-response curve in NPE cells that express EP2 receptors, making it a valuable tool for studying EP4 receptor signaling in varied biological contexts. -
Prostaglandin Analog
N-Cyclopropyl bimatoprost is a prostaglandin analog that primarily targets the prostaglandin receptors. It has been shown to exhibit significant biological activity in modulating intraocular pressure and can be utilized in research related to glaucoma and other ocular conditions. Additionally, this compound may be important for investigating epithelial-associated pathologies, providing insights into its therapeutic potential. -
Enantiomer
15β-Travoprost is an enantiomer of Travoprost that functions as a selective full agonist of the FP prostaglandin receptor. It exhibits high affinity for the receptor and is primarily used in research applications focusing on glaucoma treatment and intraocular pressure modulation. This compound's unique chemical properties make it a valuable tool in studying FP receptor-related biological processes and developing therapeutic strategies targeting ocular conditions. -
Endogenous Hormone
Prostaglandin D2 serinol amide is an endogenous hormone that acts as a weak inhibitor of the hydrolysis of [3H]2-oleoylglycerol. This compound is relevant for studies investigating lipid metabolism and signaling pathways associated with inflammatory responses. Its unique mechanism makes it a valuable tool for researchers exploring the role of prostaglandins in various physiological and pathophysiological processes. -
Thromboxane Synthetase Inhibitor
Dazoxiben is an effective thromboxane synthetase inhibitor that functions to reduce thromboxane production, thereby influencing platelet aggregation and vasoconstriction. This compound is particularly relevant in the investigation of vascular conditions, such as Raynaud's syndrome, where thromboxane overproduction may play a critical role. Its oral bioavailability makes it suitable for in vivo studies on thromboxane-related pathologies. -
Bronchoconstrictor
16,16-Dimethylprostaglandin E1 is a synthetic analog of prostaglandin E1 that primarily acts as a bronchoconstrictor by inducing contraction of smooth muscle tissue. Its ability to elicit vascular smooth muscle contractions makes it valuable in studying respiratory function and vascular dynamics. Additionally, 16,16-Dimethylprostaglandin E1 has been shown to suppress cellular elongation induced by indomethacin, providing insights into its potential applications in inflammatory research. -
TP Agonist
I-BOP is a potent thromboxane A2 receptor (TP) agonist with a binding affinity (KD) of 0.61 nM. It facilitates cellular proliferation by activating the PI3K signaling pathway in vascular smooth muscle cells. Additionally, I-BOP exhibits a biphasic, dose-dependent modulation of excitatory postsynaptic potentials in hippocampal neurons, making it a valuable tool for research in vascular biology and neurophysiology. -
EP1 Antagonist
MF266-1 is a selective antagonist of the E prostanoid receptor 1 (EP1), demonstrating a Ki value of 3.8 nM. It exhibits moderate selectivity for the thromboxane A2 receptor (TP). This compound has potential applications in the research of arthritis and related inflammatory conditions. -
TXA2/H1 antagonist
KF15766 is an orally active dual antagonist of thromboxane A2 (TXA2) and histamine H1 receptors, exhibiting inhibition constants (Kis) of 740 nM and 20 nM, respectively. This compound demonstrates significant potential for therapeutic applications in antiallergic research, allowing for the exploration of its effects on allergic responses and related disorders. Its dual-target mechanism makes KF15766 an important tool in the study of asthma and other allergic conditions. -
Prostacyclin Agonist
BMY 42393 is an orally active prostacyclin agonist that modulates monocyte and macrophage functions, effectively suppressing their atherogenic activity and cytokine production. This compound is particularly valuable for research focused on atherosclerosis and its related mechanisms, providing insights into cardiovascular health and inflammatory response pathways. -
IOP Reducing Agent
PGF2α-isopropyl ester is a derivative of Prostaglandin F2α that functions as an intraocular pressure (IOP) reducing agent. It primarily enhances the uveoscleral outflow of aqueous humor, effectively decreasing IOP. This compound is utilized in research related to glaucoma and related ocular conditions, though it may cause side effects such as conjunctival hyperemia and ocular irritation. -
PGHS-2 Inhibitor
15(S)-HpEPE is a lipoxygenase-derived hydrolysis product of polyunsaturated fatty acids (PUFAs), serving as a potential inhibitor of prostaglandin H synthase 2 (PGHS-2). This compound has been shown to downregulate PGHS-2 expression, making it a valuable tool for research focused on inflammatory pathways and associated diseases. Its biological activity is of interest in studies examining the modulation of prostaglandin synthesis and the regulation of inflammatory responses. -
15(R) Stereoisomer of PGA1
15-epi Prostaglandin A1 (15-epi PGA1) is the 15(R) stereoisomer of Prostaglandin A1. This compound primarily induces renal vasodilation, enhances the excretion of sodium in urine, and lowers arterial pressure in hypertensive models. Its biological activity makes it a valuable tool for research in cardiovascular and renal physiology, as well as studies focused on hypertension. -
PTGR2 Inhibitor
RJG-2036 is a potent covalent inhibitor of human prostaglandin reductase 2 (PTGR2) with an IC50 value of 100 nM. This compound effectively inhibits NADPH-dependent reduction, leading to a significant decrease in the secretion of proinflammatory cytokines such as TNF-α and various eicosanoids in LPS-stimulated THP-1 macrophages. RJG-2036 serves as a valuable tool for investigating the molecular mechanisms underlying inflammatory diseases.
